VistaGen Therapeutics Inc. (VTGN) Stock Price

0.59 ▼ -0.06 (-9.23%)
Open: 0.61 Vol: 41K Day's range: 0.59 - 0.62 Aug 23, 16:00 EDT
IEX Real-Time Price
Free Stock Screener
Loading chart ...
VTGN Technical Analysis
5 mins 30 mins Hourly Daily Weekly
NEUTRAL BUY BUY SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 0.63▼ 0.62▼ 0.62▼ 0.61▼ 0.55▲
MA10 0.62▲ 0.61▲ 0.61▲ 0.56▲ 0.62▼
MA20 0.62▼ 0.60▲ 0.60▲ 0.55▲ 0.73▼
MA50 0.57▲ 0.55▲ 0.55▲ 0.66▼ 1.25▼
MA100 0.60▲ 0.63▼ 0.65▼ 0.86▼ 1.23▼
MA200 0.68▼ 0.77▼ 0.82▼ 1.28▼ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD -0.001▼ 0.001▲ 0.002▲ 0.019▲ N/A    
RSI 52.695▲ 54.055▲ 53.887▲ 49.555▼ 36.324▼
STOCH 69.479     57.606     57.606     73.664     23.082    
WILL %R -36.445     -42.288     -42.288     -30.000     -72.439    
CCI -8.703     -4.968     -4.968     66.520     -68.504    
Latest Filters Detected On VTGN
CDL $VTGN Harami Candlestick Pattern Detected Set Alert
▼ GAP $VTGN Open Gap Down %2 Set Alert
▼ GAP $VTGN Open Gap Down %3 Set Alert
▼ GAP $VTGN Open Gap Down %5 Set Alert
RSI $VTGN RSI(14) Crossed Below 50 Set Alert
VistaGen Therapeutics Inc. News
VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder
Thursday, August 15, 2019 05:43 AM
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 15, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system ...
VistaGen Therapeutics, Inc.: VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
Tuesday, August 13, 2019 01:32 PM
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system ...
Vistagen Shares Fall Under $1 After Depression Drug Flunks Midstage Trial
Thursday, May 02, 2019 09:20 AM
Vistagen Therapeutics Inc (NASDAQ: VTGN) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatment-resistant depression (TRD) drug candidate.
VTGN historical stock data
date open high low close volume
23/08/19 0.61 0.62 0.59 0.59 41,000
22/08/19 0.5612 0.65 0.5612 0.65 121,090
21/08/19 0.61 0.65 0.56 0.60 331,900
20/08/19 0.65 0.65 0.59 0.6097 208,992
19/08/19 0.49 0.63 0.49 0.61 455,700
16/08/19 0.50 0.53 0.50 0.51 190,600
15/08/19 0.58 0.58 0.48 0.50 264,100
14/08/19 0.49 0.56 0.48 0.48 172,900
13/08/19 0.5054 0.54 0.47 0.512 344,497
12/08/19 0.50 0.55 0.45 0.55 117,600
Quote Details
52wk Low:0.43
52wk High:2.44
Vol:41K
Avg Vol(3m):2.9M
1Y Chng:-52.03%
1M Chng:-21.33%
Add to Watch List
More Information
Index NASDAQ Composite
Market Cap. 25.99M